Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 2, 2012, Pages 207-215

  Carrero, Juan Jesus ^a,b   Kyriazis, John ^c   Sonmez, Alper ^d   Tzanakis, Ioannis ^d   Qureshi, Abdul Rashid ^a   Stenvinkel, Peter ^a   Saglam, Mutlu ^d   Stylianou, Kostas ^d   Yaman, Halil ^e   Taslipinar, Abdullah ^d   Vural, Abdulgaffar ^f   Gok, Mahmut ^f   Yenicesu, Mujdat ^f   Daphnis, Eugene ^d   Yilmaz, Mahmut Ilker ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c General Hospital of Chios   (Greece)

^d GULHANE SCHOOL OF MEDICINE   (Turkey)

^e General Hospital of Chania   (Greece)

^f UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; HEMOGLOBIN; PHOSPHATE; PROLACTIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PULSE WAVE;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; GREECE; HEMODYNAMICS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROLACTIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULSATILE FLOW; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VASODILATION;

EID: 84857150059     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06840711     Document Type: Article

References (43)

1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW: Cardiovascular and non-cardiovascular mortality among patients starting dialysis. JAMA 302: 1782-1789, 2009
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
3. Zoccali C: Endothelial dysfunction and the kidney: Emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 17[Suppl 2]: S61-S63, 2006
4. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease- What have we learned in 10 years? Semin Dial 23: 498-509, 2010
5. Hou SH, Grossman S, Molitch ME: Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 6: 245-249, 1985
6. Cowden EA, Ratcliffe WA, Ratcliffe JG, Dobbie JW, Kennedy AC: Hyperprolactinaemia in renal disease. Clin Endocrinol (Oxf) 9: 241-248, 1978
7. Yavuz D, Topçu G, Ozener C, Akalin S, Sirikçi O: Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy. Clin Endocrinol (Oxf) 63: 520-524, 2005
8. McKenna TM, Woolf PD: Prolactin metabolic clearance and resistance to dopaminergic suppression in acute uremia. Endocrinology 116: 2003-2007, 1985
9. Caticha O, Norato DY, Tambascia MA, Santana A, Stephanou A, Sarlis NJ: Total body zinc depletion and its relationship to the development of hyperprolactinemia in chronic renal insufficiency. J Endocrinol Invest 19: 441-448, 1996
10. Stumpe KO, Kolloch R, Higuchi M, Krück F, Vetter H: Hyper-prolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopa-mine control. Lancet 2: 211-214, 1977
11. Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, Daniel WG, Lohmann T, Garlichs CD: Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression. Horm Metab Res 38: 767-772, 2006
12. Wallaschofski H, Lohmann T, Hild E, Kobsar A, Siegemund A, Spilcke-Liss E, Hentschel B, Stumpf C, Daniel WG, Garlichs CD, Eigenthaler M: Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost 96: 38-44, 2006
13. Wallaschofski H, Eigenthaler M, Kiefer M, Donné M, Hentschel B, Gertz HJ, Lohmann T: Hyperprolactinemia in patients on an-tipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: Pilot study. J Clin Psychopharmacol 23: 479-483, 2003
14. Marlettini MG, Cassani A, Morselli Labate AM, Rusticali AG, Crippa S, Trabatti M, Miniero R, Plate L, Orlandi C: Role of prolactin in pregnancy hypertension. Clin Exp Hypertens A 9: 1099-1119, 1987
15. Leaños-Miranda A, Márquez-Acosta J, Cárdenas-Mondragón GM, Chinolla-Arellano ZL, Rivera-Leaños R, Bermejo-Huerta S, Romero-Arauz JF, Alvarez-Jiménez G, Ramos-León JC, Ulloa-Aguirre A: Urinary prolactin as a reliable marker for pre-eclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab 93: 2492-2499, 2008
16. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H: A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardio-myopathy. Cell 128: 589-600, 2007
17. Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M: Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl 34: 217-224, 2011
18. Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT: Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2: 389-395, 2009
19. Gungor O, Kircelli F, Carrero JJ, Asci G, Toz H, Tatar E, Hur E, Sever MS, Arinsoy T, Ok E: Endogenous testosterone and mortality in male hemodialysis patients: Is it the result of aging? Clin J Am Soc Nephrol 5: 2018-2023, 2010
20. Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Bárány P, Heimbürger O, Stenvinkel P: Low serum testosterone increases mortality risk among maledialysis patients.J AmSoc Nephrol20: 613-620, 2009
21. Karakitsos D, Patrianakos AP, De Groot E, Boletis J, Karabinis A, Kyriazis J, Samonis G, Parthenakis FI, Vardas PE, Daphnis E: Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 26: 536-543, 2006
22. Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, Bárány P, Heimbürger O, Stenvinkel P:Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 26: 184-190, 2011
23. Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, Eyileten T, Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU, Yenicesu M, Carrero JJ: Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 6: 1617-1625, 2011
24. Kyriazis J, Tzanakis I, Stylianou K, Katsipi I, Moisiadis D, Papadaki A, Mavroeidi V, Kagia S, Karkavitsas N, Daphnis E: Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transplant 26: 2971-2977, 2011
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
26. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Altun B, Yenicesu M, Carrero JJ: Vascular health, systemic inflammation and progressive reduction in kidney function: Clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 6: 3537-3543, 2011
27. Snyder PJ, Cooper DS, Martin KI: Causes of hyperprolactinemia. Version 18.2, October 2010. Available at: http://www.uptodate.com/contents/causes-of-hyperprolactinemia. Accessed December 2, 2011
28. Sauro MD, Buckley AR, Russell DH, Fitzpatrick DF: Prolactin stimulation of protein kinase C activity in rat aortic smooth muscle. Life Sci 44: 1787-1792, 1989
29. Aziz MM, Ishihara S, Rumi MA, Mishima Y, Oshima N, Kadota C, Moriyama I, Li YY, Rahman FB, Otani A, Oka A, Ishimura N, Kadowaki Y, Amano Y, Kinoshita Y: Prolactin induces MFG-E8 production in macrophages via transcription factor C/EBPbeta-dependent pathway. Apoptosis 13: 609-620, 2008
30. Bresson JL, Jeay S, Gagnerault MC, Kayser C, Beressi N, Wu Z, Kinet S, Dardenne M, Postel-Vinay MC: Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: Relation with age and GH-binding protein. Endocrinology 140: 3203-3209, 1999
31. Sun R, Li AL, Wei HM, Tian ZG: Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines. Cell Res 14: 67-73, 2004
32. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP, Papamichael C: Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54: 98-105, 2009
33. Stamatelopoulos KS, Georgiopoulos GA, Sfikakis PP, Kollias G, Manios E, Mantzou E, Kyrkou K, Zakopoulos N, Papamichael CM, Alevizaki M: Pilot study of circulating prolactin levels and endothelial function in men with hypertension. Am J Hypertens 24: 569-573, 2011
34. Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, Surico N, Vacca G: Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 148: 4080-4090, 2007
35. Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmark S, Witt MR, Bárány P, Heimbürger O, Suliman ME, Alvestrand A, Lindholm B, Stenvinkel P: Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 262: 690-701, 2007
36. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray J, Yamac H, Labidi S, Struman I, Hilfiker-Kleiner D: Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: A proof-of-concept pilot study. Circulation 121: 1465-1473, 2010
37. Hilfiker-Kleiner D, Meyer GP, Schieffer E, Goldmann B, Podewski E, Struman I, Fischer P, Drexler H: Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 50: 2354-2355, 2007
38. Vircburger MI, Prelević GM, Perić LA, Knezević J, Djukanović L: Testosterone levels after bromocriptine treatment in patients undergoing long-term hemodialysis. J Androl 6: 113-116, 1985
39. Ramirez G, Butcher DE, Newton JL, Brueggemeyer CD, Moon J, Gomez-Sanchez C: Bromocriptine and the hypothalamic hypo-physeal function in patients with chronic renal failure on chronic hemodialysis. Am J Kidney Dis 6: 111-118, 1985
40. Bommer J, Ritz E, del Pozo E, Bommer G: Improved sexual function in male haemodialysis patients on bromocriptine. Lancet 2: 496-497, 1979
41. Mejía-Rodríguez O, Alvarez-Aguilar C, Vega-Gómez HE, Belio-Caro F, Vargas-Espinosa JM, Paniagua-Sierra JR: Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients. Proc West Pharmacol Soc 48: 122-125, 2005
42. Mejía-Rodríguez O, Alvarez-Aguilar C, Ledesma-Ramírez M, Paniagua-Sierra R: Therapeutic effect of bromocriptine together with the established treatment for hypertension in patients undergoing peritoneal dialysis. Proc West Pharmacol Soc 47: 122- 124, 2004
43. Degli Esposti E, Sturani A, Santoro A, Zuccalà A, Chiarini C, Zucchelli P: Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Clin Sci (Lond) 69: 51-56, 1985